John E Delaney

US Patent:

20150284471, Oct 8, 2015

Filed:

Dec 7, 2012

Appl. No.:

14/363777

Inventors:

- Thousand Oaks CA, US
Michael Wittekind - New Canaan CT, US
John M. Delaney - Bellevue WA, US
Mingyue Zhou - Union City CA, US
Derek E. Piper - Santa Clara CA, US

International Classification:

C07K 16/40
A61K 45/06
A61K 39/395

Abstract:

Antigen binding proteins that activate LCAT are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to modulate HDL particle size, increase plasma levels of HDL-C, and increase reverse cholesterol transport. Accordingly, the antigen binding proteins have utility in the treatment and prevention of atherosclerosis, various cardiovascular diseases and cholesterol-related disorders, inflammatory conditions, thrombosis-related conditions, metabolic syndrome, diabetes and insulin-resistance. The LCAT antigen binding proteins are also useful in treating the consequences, symptoms, and/or pathology associated with either genetic or acquired LCAT deficiency, including chronic kidney disease (CKD).